Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Soap makers named in Prop 65 suit

This article was originally published in The Tan Sheet

Executive Summary

Four companies did not reasonably warn about the presence of the carcinogen 1,4-dioxane in their body washes, gels and soap products, according to a May 29 complaint filed by California State Attorney General Jerry Brown. The lawsuit alleges Avalon Natural Products, Beaumont Products, NutriBiotic and Whole Foods Market California knowingly exposed consumers to a chemical known to "cause cancer or reproductive toxicity" per California's Proposition 65, which requires warnings about potential health risks of chemical contents...

You may also be interested in...



Canada Proposes 14 New Entries To List Of Recognized Device Standards

The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.

The Race To Vaccinate The World Against COVID-19

Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.

Innovent Expands Internationally With Indonesia Deal

Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel